Technology

Akero Therapeutics

$31.06
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.17 (+3.91%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell AKRO and other stocks, options, and ETFs commission-free!

About AKRO

Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA. The listed name for AKRO is Akero Therapeutics, Inc. Common Stock.

CEO
Andrew Cheng
Employees
13
Headquarters
South San Francisco, California
Founded
2017
Market Cap
1.09B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
483.41K
High Today
$31.15
Low Today
$29.64
Open Price
$29.64
Volume
182.19K
52 Week High
$41.16
52 Week Low
$10.78

Collections

AKRO Earnings

-$2.21
-$1.47
-$0.74
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 15, After Hours

You May Also Like

RMBS
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure